Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Peroxisomal biogenesis factor 1 (PEX1) is an ATPase of the AAA protein family, functioning as a peroxin essential for the formation, maintenance, and protein import machinery of peroxisomes[1][3][5][7]. PEX1, in complex with PEX6, forms a heterohexameric AAA-ATPase that uses ATP-driven conformational changes to extract the peroxisomal import receptor PEX5 from the peroxisomal membrane, thus recycling it for further rounds of matrix enzyme import[5][6][7]. Mutations in PEX1 disrupt peroxisome assembly and function, and are the leading genetic cause of Zellweger spectrum disorders, including Zellweger syndrome, neonatal adrenoleukodystrophy, and infantile Refsum disease[1][2][3][5]. These diseases present as devastating, multisystem, usually lethal pediatric disorders caused by failure of peroxisome biogenesis and resultant defects in lipid metabolism and detoxification pathways[1][2][5][7]. No approved drugs directly target PEX1; current medical interest is genetic and diagnostic, not pharmacologic.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Peroxisomal biogenesis factor 1 (PEX1).